Open the filing on EDGARCHARLES RIVER LABORATORIES ANNOUNCES
THIRD-QUARTER 2025 RESULTS
- Third-Quarter Revenue of $1.00 Billion -
- Third-Quarter GAAP Earnings per Share of $1.10
and Non-GAAP Earnings per Share of $2.43 -
WILMINGTON, MA, November 5, 2025 - Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2025. For the quarter, revenue was $1.00 billion, a decrease of 0.5% from $1.01 billion in the third quarter of 2024.
The impact of foreign currency translation increased reported revenue by 1.3%, and the divestiture of a small Safety Assessment site in 2024 reduced reported revenue by 0.2%. Excluding the effect of these items, revenue declined 1.6% on an organic basis. On a segment basis, lower revenue in the Discovery and Safety Assessment (DSA) and Manufacturing Solutions (Manufacturing) segments were partially offset by organic revenue growth in the Research Models and Services (RMS) segment.
In the third quarter of 2025, the GAAP operating margin increased to 13.3% from 11.6% in the third quarter of 2024, primarily driven by lower costs associated with the Company's restructuring initiatives. GAAP net income available to common shareholders for the third quarter of 2025 was $54.4 million, or $1.10 per diluted share, a decrease from net earnings of $68.7 million, or $1.33 per diluted share, for the same period in 2024. The decreases in GAAP net income and earnings per share were primarily driven by a loss from certain venture capital and other strategic investments of $0.33 per share in the third quarter of 2025, compared to a $0.03 gain last year.
On a non-GAAP basis, the third-quarter operating margin decreased to 19.7% from 19.9% in the third quarter of 2024, primarily as a result of lower revenue. Non-GAAP net income was $120.3 million for the third quarter of 2025, a decrease of 10.0% from $133.7 million for the same period in 2024. Third-quarter diluted earnings per share on a non-GAAP basis were $2.43, a decrease of 6.2% from $2.59 per share for the third quarter of 2024. The non-GAAP net income and earnings per share decreases were driven primarily by lower revenue and a higher tax rate, partially offset by lower interest expense, as well as a reduction in diluted shares outstanding from stock repurchases.
James C. Foster, Chair, President and Chief Executive Officer, said, “Our solid third-quarter financial results demonstrate that the demand for our extensive portfolio of early-stage research and manufacturing products and services remains stable. We believe that positive signals are beginning to emerge which indicate that the industry may be on a path towards recovery; however, sustained improvement in our business will take time. There is still some uncertainty in the healthcare sector, so we are remaining cautious at this time.”
"In this environment, we believe it is critical to remain intently focused on our strategy to further differentiate ourselves from the competition through our science and our innovative solutions, implement additional initiatives to unlock value, and gain additional share of our clients’ drug development and manufacturing programs. This focus on our strategy and our science positions us extremely well to lead the industry through advances in drug development," Mr. Foster concluded.
Third-Quarter Segment Results
Research Models and Services (RMS)
Revenue for the RMS segment was $213.5 million in the third quarter of 2025, an increase of 7.9% from $197.8 million in the third quarter of 2024. The impact of foreign currency translation increased revenue by 1.4%. Organic revenue increased by 6.5%, due primarily to higher revenue for large research model products.
In the third quarter of 2025, the RMS segment’s GAAP operating margin increased to 16.2% from 13.9% in the third quarter of 2024. On a non-GAAP basis, the operating margin increased to 25.0% from 21.0%. The GAAP and non-GAAP operating margin increases were primarily driven by the favorable revenue mix related to large research models, as well as the benefit of cost savings resulting from the Company's restructuring initiatives.
Discovery and Safety Assessment (DSA)
Revenue for the DSA segment was $600.7 million in the third quarter of 2025, a decrease of 2.3% from $615.1 million in the third quarter of 2024. The impact of foreign currency translation increased DSA revenue by 1.2% and the divestiture of a small DSA site reduced reported revenue by 0.4%. Organic revenue decreased by 3.1%, driven primarily by lower sales volume for both discovery and regulated safety assessment services.
In the third quarter of 2025, the DSA segment’s GAAP operating margin decreased to 20.5% from 20.6% in the third quarter of 2024. On a non-GAAP basis, the operating margin decreased to 25.4% from 27.4% in the third quarter of 2024. The GAAP and non-GAAP operating margin decreases were primarily driven by lower revenue.
Manufacturing Solutions (Manufacturing)
Revenue for the Manufacturing segment was $190.7 million in the third quarter of 2025, a decrease of 3.1% from $196.9 million in the third quarter of 2024. The impact of foreign currency translation increased Manufacturing revenue by 2.0%. Organic revenue decreased 5.1%, primarily driven by lower revenue in the CDMO and Biologics Testing businesses, partially offset by higher revenue in the Microbial Solutions business.
The Manufacturing segment’s GAAP operating margin increased to 20.9% from 20.4% in the third quarter of 2024 as a result of lower acquisition-related amortization adjustments in the CDMO business and lower costs associated with the Company's restructuring initiatives. On a non-GAAP basis, the operating margin decreased to 26.7% from 28.7% in the third quarter of 2024, driven primarily by lower revenue in the CDMO business.
Updates 2025 Guidance
The Company is updating its 2025 financial guidance, which was previously updated on August 6, 2025. The Company is narrowing its full-year outlook for revenue and non-GAAP earnings per share to the middle and upper ends of the previous ranges, respectively, to primarily reflect the third-quarter financial performance, which modestly exceeded the Company's prior outlook.
The Company’s 2025 guidance for revenue and earnings per share is as follows:
| 2025 GUIDANCE | CURRENT | PRIOR |
| Revenue growth/(decrease), reported | (1.5)% - (0.5)% | (2.5)% - (0.5)% |
| Impact of divestitures/(acquisitions), net | N/M | N/M |
| (Favorable)/unfavorable impact of foreign exchange | ~(1.0)% | ~(0.5)% |
| Revenue growth/(decrease), organic (1) | (2.5)% - (1.5)% | (3.0)% - (1.0)% |
| GAAP EPS estimate | $4.15 - $4.35 | $4.25 - $4.65 |
| Acquisition-related amortization and other acquisition- and integration-related costs (2) | ~$3.65 | ~$3.60 |
| Costs associated with restructuring actions (3) | ~$1.30 | ~$1.40 |
| Certain venture capital and other strategic investment losses/(gains), net (4) | $0.50 | ~$0.17 |
| Other items (5) | ~$0.50 | ~$0.50 |
| Non-GAAP EPS estimate | $10.10 - $10.30 | $9.90 - $10.30 |
Footnotes to Guidance Table:
(1) Organic revenue growth is defined as reported revenue growth adjusted for completed acquisitions and divestitures, as well as foreign currency translation.
(2) These adjustments include amortization related to intangible assets, inclusive of the acceleration of amortization expense related to certain CDMO client relationships, as well as the purchase accounting step-up on inventory and certain long-term biological assets. In addition, these adjustments include some costs related to the evaluation and integration of acquisitions and divestitures.
(3) These adjustments primarily include site consolidation (including site transition costs), severance, impairment, and other costs related to the Company’s restructuring actions.
(4) Certain venture capital and other strategic investment performance only includes recognized gains or losses on certain investments. The Company does not forecast the future performance of these investments.
(5) These items primarily relate to (i) certain third-party legal costs related to investigations by the U.S. government into the NHP supply chain related to our DSA segment; (ii) additionally included within the DSA segment, due to the utilization of NHPs, are reductions to the previous $27 million inventory charge incurred during fiscal 2024, to write down inventory associated with the Cambodia-sourced NHP matter from February 16, 2023, as a result of the cases being closed during fiscal 2025; and (iii) certain third-party advisory costs related to the Company entering into a Cooperation Agreement with a shareholder.
Webcast
Charles River has scheduled a live webcast on Wednesday, November 5, at 9:00 a.m. ET to discuss matters relating to this press release. To participate, please go to ir.criver.com and select the webcast link. You can also find the associated slide presentation and reconciliations of GAAP financial measures to non-GAAP financial measures on the website.
Non-GAAP Reconciliations
The Company reports non-GAAP results in this press release, which exclude often-one-time charges and other items that are outside of normal operations. A reconciliation of GAAP to non-GAAP results is provided in the schedules at the end of this press release.
Use of Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, such as non-GAAP earnings per diluted share, non-GAAP operating income, non-GAAP operating margin, and non-GAAP net income. Non-GAAP financial measures exclude, but are not limited to, the amortization of intangible assets and the purchase accounting step-up adjustment on inventory and certain long term biological assets, and other charges and adjustments related to our acquisitions and divestitures, including incremental dividends attributable to Noveprim noncontrolling interest holders; expenses associated with evaluating and integrating acquisitions and divestitures, including advisory fees and certain other transaction-related costs, as well as fair value adjustments associated with contingent consideration; charges, gains, and losses attributable to businesses or properties we plan to close, consolidate, or divest; severance and other costs associated with our restructuring initiatives; the write-off of deferred financing costs and fees related to debt financing; investment gains or losses associated with our venture capital and certain other strategic equity investments; certain legal costs in our Microbial Solutions business related to environmental litigation and in our DSA segment related to U.S. government investigations into the NHP supply chain and advisory costs related to entering into a Cooperation Agreement with a shareholder; tax effect of all of the aforementioned matters; and adjustments related to the recognition of deferred tax assets expected to be utilized as a result of changes to the our international financing structure and the revaluation of deferred tax liabilities as a result of foreign tax legislation. This press release also refers to our revenue on both a GAAP and non-GAAP basis: on a non-GAAP basis, we define “organic revenue growth” as reported revenue growth adjusted for foreign currency translation, acquisitions, and divestitures. We exclude these items from the non-GAAP financial measures because they are outside our normal operations. There are limitations in using non-GAAP financial measures, as they are not presented in accordance with generally accepted accounting principles, and may be different than non-GAAP financial measures used by other companies. In particular, we believe that the inclusion of supplementary non-GAAP financial measures in this press release helps investors to gain a meaningful understanding of our core operating results and future prospects without the effect of these often-one-time charges, and is consistent with how management measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts. We believe that the financial impact of our acquisitions and divestitures (and in certain cases, the evaluation of such acquisitions and divestitures, whether or not ultimately consummated) is often large relative to our overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis. In addition, certain activities and their underlying associated costs, such as business acquisitions, generally occur periodically but on an unpredictable basis. We calculate non-GAAP integration costs to include third-party integration costs incurred post-acquisition. Presenting revenue on an organic basis allows investors to measure our revenue growth exclusive of acquisitions, divestitures, and foreign currency exchange fluctuations more clearly. Non-GAAP results also allow investors to compare the Company’s operations against the financial results of other companies in the industry who similarly provide non-GAAP results. The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations presented in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. Reconciliations of the non-GAAP financial measures used in this press release to the most directly comparable GAAP financial measures are set forth in this press release, and can also be found on the Company’s website at ir.criver.com.
Caution Concerning Forward-Looking Statements
Forward-looking statements notice
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “will,” “would,” “may,” “estimate,” “plan,” “outlook,” and “project,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding Charles River’s expectations regarding the availability of Cambodia-sourced NHPs; the impact of the investigations by the U.S. government into the Cambodia NHP supply chain, including but not limited to Charles River’s ability to cooperate fully with the U.S. government; Charles River’s ability to effectively manage any Cambodia NHP supply impact; the projected future financial performance of Charles River and our specific businesses, including our expectations with respect to the impact of NHP supply constraints and our ability to gain market share; earnings per share; operating margin; client demand, particularly the future demand for drug discovery and development products and services, including our expectations for future revenue trends; our expectations with respect to pricing of our products and services; our expectations with respect to future tax rates and the impact of such tax rates on our business; our expectations with respect to the impact of acquisitions and divestitures on the Company, our service offerings, client perception, strategic relationships, revenue, revenue growth rates, revenue growth drivers, and earnings; the development and performance of our services and products, including our investments in our portfolio; market and industry conditions including the outsourcing of services and identification of spending trends by our clients and funding available to them; ability to gain market share and capitalize on business opportunities; the impact of our restructuring initiatives, including annualized savings; the impact of our stock repurchase authorization; and Charles River’s future performance, including as delineated in our forward-looking guidance, and particularly our expectations with respect to revenue, the impact of foreign exchange, interest rates, enhanced efficiency initiatives. Forward-looking statements are based on Charles River’s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: the timing of the resumption of Cambodia NHP imports into the U.S., our ability to manage supply impact, and potential study delays in our DSA segment attributable to NHP supply constraints; changes and uncertainties in the global economy and financial markets; the ability to successfully integrate businesses we acquire; the timing and magnitude of our share repurchases; negative trends in research and development spending, negative trends in the level of outsourced services, or other cost reduction actions by our clients; the ability to convert backlog to revenue; special interest groups; contaminations; industry trends; new displacement technologies; USDA and FDA regulations; changes in law; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; disruptions in the global economy caused by geopolitical conflicts; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 19, 2025, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this press release except as required by law.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Investor Contact: Media Contact:
Todd Spencer Amy Cianciaruso
Corporate Vice President, Corporate Senior Vice President,
Investor Relations Chief Communications Officer
781.222.6455 781.222.6168 todd.spencer@crl.com amy.cianciaruso@crl.com
| Three Months Ended | Nine Months Ended |
|---|
| September 27, 2025 | September 28, 2024 | September 27, 2025 | September 28, 2024 |
|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | |
| SCHEDULE 1 | |
| CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) | |
| (in thousands, except for per share data) | |
| Service revenue | $808,042 | $832,463 | $2,446,801 | $2,492,225 |
| Product revenue | 196,810 | 177,300 | 574,354 | 555,215 |
| Total revenue | 1,004,852 | 1,009,763 | 3,021,155 | 3,047,440 |
| Costs and expenses: | | | | |
| Cost of services provided (excluding amortization of intangible assets) | 572,635 | 568,699 | 1,734,939 | 1,724,246 |
| Cost of products sold (excluding amortization of intangible assets) | 93,425 | 92,043 | 272,625 | 275,617 |
| Selling, general and administrative | 177,589 | 199,213 | 546,937 | 555,295 |
| Amortization of intangible assets | 27,404 | 32,403 | 158,052 | 97,248 |
| Operating income | 133,799 | 117,405 | 308,602 | 395,034 |
| Other income (expense): | | | | |
| Interest income | 1,422 | 1,528 | 3,923 | 6,740 |
| Interest expense | (25,403) | (30,284) | (83,254) | (98,054) |
| Other income (expense), net | (22,618) | 2,592 | (34,675) | 6,185 |
| Income before income taxes | 87,200 | 91,241 | 194,596 | 309,905 |
| Provision for income taxes | 31,644 | 20,946 | 60,469 | 70,867 |
| Net income | 55,556 | 70,295 | 134,127 | 239,038 |
| Less: Net income attributable to noncontrolling interests | 1,134 | 638 | 1,910 | 2,340 |
| Net income attributable to Charles River Laboratories International, Inc. | $54,422 | $69,657 | $132,217 | $236,698 |
| Calculation of net income per share attributable to Charles River Laboratories International, Inc. common shareholders | | | | |
| Net income attributable to Charles River Laboratories International, Inc. | $54,422 | $69,657 | $132,217 | $236,698 |
| Less: Adjustment of redeemable noncontrolling interest | - | 379 | - | 1,081 |
| Less: Incremental dividends attributed to noncontrolling interest holders | - | 599 | - | 9,621 |
| Net income available to Charles River Laboratories International, Inc. common shareholders | $54,422 | $68,679 | $132,217 | $225,996 |
| Earnings per common share | | | | |
| Basic | $1.11 | $1.34 | $2.66 | $4.39 |
| Diluted | $1.10 | $1.33 | $2.65 | $4.37 |
| Weighted-average number of common shares outstanding | | | | |
| Basic | 49,213 | 51,394 | 49,680 | 51,461 |
| Diluted | 49,426 | 51,583 | 49,866 | 51,713 |
| September 27, 2025 | December 28, 2024 |
|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. |
| SCHEDULE 2 |
| CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) |
| (in thousands, except per share amounts) |
| Assets | | |
| Current assets: | | |
| Cash and cash equivalents | $207,097 | $194,606 |
| Trade receivables and contract assets, net of allowances for credit losses of $13,805 and $18,301, respectively | 734,482 | 720,915 |
| Inventories | 302,550 | 278,544 |
| Prepaid assets | 121,535 | 103,210 |
| Other current assets | 166,440 | 105,796 |
| Total current assets | 1,532,104 | 1,403,071 |
| Property, plant and equipment, net | 1,591,625 | 1,604,014 |
| Venture capital and strategic equity investments | 194,635 | 218,350 |
| Operating lease right-of-use assets, net | 374,273 | 412,490 |
| Goodwill | 2,922,281 | 2,846,608 |
| Intangible assets, net | 571,094 | 723,400 |
| Deferred tax assets | 36,907 | 42,179 |
| Other assets | 290,893 | 278,233 |
| Total assets | $7,513,812 | $7,528,345 |
| Liabilities, Redeemable Noncontrolling Interests and Equity | | |
| Current liabilities: | | |
| Accounts payable | $169,615 | $140,337 |
| Accrued compensation | 269,697 | 179,418 |
| Deferred revenue | 237,728 | 248,322 |
| Accrued liabilities | 228,895 | 232,010 |
| Other current liabilities | 215,953 | 194,014 |
| Total current liabilities | 1,121,888 | 994,101 |
| Long-term debt, net and finance leases | 2,185,453 | 2,240,205 |
| Operating lease right-of-use liabilities | 443,185 | 483,789 |
| Deferred tax liabilities | 123,007 | 106,960 |
| Other long-term liabilities | 189,462 | 195,212 |
| Total liabilities | 4,062,995 | 4,020,267 |
| Redeemable noncontrolling interests | 40,492 | 41,126 |
| Equity: | | |
| Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding | - | - |
| Common stock, $0.01 par value; 120,000 shares authorized; 51,351 shares issued and 49,215 shares outstanding as of September 27, 2025, and 51,141 shares issued and outstanding as of December 28, 2024 | 514 | 511 |
| Additional paid-in capital | 2,015,665 | 1,966,237 |
| Retained earnings | 1,944,317 | 1,812,100 |
| Treasury stock, at cost, 2,136 and zero shares, as of September 27, 2025 and December 28, 2024, respectively | (363,431) | - |
| Accumulated other comprehensive loss | (191,616) | (317,345) |
| Total Charles River Laboratories International, Inc. equity | 3,405,449 | 3,461,503 |
| Nonredeemable noncontrolling interest | 4,876 | 5,449 |
| Total equity | 3,410,325 | 3,466,952 |
| Total liabilities, redeemable noncontrolling interests and equity | $7,513,812 | $7,528,345 |
| Nine Months Ended |
|---|
| September 27, 2025 | September 28, 2024 |
|---|
| Cash flows relating to operating activities | | |
|---|
| Net income | $134,127 | $239,038 |
|---|
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
|---|
| Depreciation and amortization | 325,035 | 259,637 |
|---|
| Long-lived asset impairments | 36,185 | 17,339 |
|---|
| Stock-based compensation | 53,451 | 52,656 |
|---|
| Deferred income taxes | (15,122) | (25,988) |
|---|
| Write down of inventories | 10,697 | 11,472 |
|---|
| (Gains) losses and impairments on venture capital and strategic equity investments, net | 33,955 | (8,788) |
|---|
| Provision for credit losses | 4,559 | 8,223 |
|---|
| (Gain) loss on divestitures, net | (3,376) | 659 |
|---|
| Other, net | 3,306 | 8,900 |
|---|
| Changes in assets and liabilities: | | |
|---|
| Trade receivables and contract assets, net | 8,106 | 18,300 |
|---|
| Inventories | (45,280) | 13,789 |
|---|
| Accounts payable | 40,747 | (7,095) |
|---|
| Accrued compensation | 81,870 | (1,981) |
|---|
| Deferred revenue | (12,319) | 13,583 |
|---|
| Customer contract deposits | (533) | 14,707 |
|---|
| Other assets and liabilities, net | (65,282) | (39,236) |
|---|
| Net cash provided by operating activities | 590,126 | 575,215 |
|---|
| Cash flows relating to investing activities | | |
|---|
| Capital expenditures | (130,202) | (157,351) |
|---|
| Purchases of investments and contributions to venture capital investments | (12,544) | (45,264) |
|---|
| Proceeds from sale of investments | 5,637 | 39,470 |
|---|
| Proceeds from sale of businesses and assets, net | 17,441 | - |
|---|
| Acquisition of businesses and assets, net of cash acquired | - | (5,479) |
|---|
| Other, net | 3,154 | (358) |
|---|
| Net cash used in investing activities | (116,514) | (168,982) |
|---|
| Cash flows relating to financing activities | | |
|---|
| Proceeds from long-term debt and revolving credit facility | 1,070,861 | 976,783 |
|---|
| Payments on long-term debt, revolving credit facility, and finance lease obligations | (1,141,500) | (1,316,990) |
|---|
| Proceeds from exercises of stock options | 3 | 23,110 |
|---|
| Purchase of treasury stock | (360,577) | (119,051) |
|---|
| Payments of contingent consideration | (21,822) | - |
|---|
| Purchase of remaining equity interest of other redeemable noncontrolling interests | (19,140) | (12,000) |
|---|
| Other, net | (12,687) | (26,900) |
|---|
| Net cash used in financing activities | (484,862) | (475,048) |
|---|
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 14,900 | (4,025) |
|---|
| Net change in cash, cash equivalents, and restricted cash | 3,650 | (72,840) |
|---|
| Cash, cash equivalents, and restricted cash, beginning of period | 205,570 | 284,480 |
|---|
| Cash, cash equivalents, and restricted cash, end of period | $209,220 | $211,640 |
|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. |
| SCHEDULE 3 |
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) |
| (in thousands) |
| | Three Months Ended | Nine Months Ended |
|---|
| | September 27, 2025 | September 28, 2024 | September 27, 2025 | September 28, 2024 |
|---|
| Revenue | $213,474 | $197,824 | $639,818 | $625,120 |
|---|
| Operating income | 34,553 | 27,544 | 113,944 | 100,641 |
|---|
| Operating income as a % of revenue | 16.2% | 13.9% | 17.8% | 16.1% |
|---|
| Add back: | | | | |
|---|
| Amortization related to acquisitions | 12,905 | 9,086 | 36,266 | 26,731 |
|---|
| Acquisition, integration, and divestiture-related adjustments | - | - | 14 | 337 |
|---|
| Severance | 136 | 2,651 | 3,664 | 3,685 |
|---|
| Asset impairment | 4,635 | 1,266 | 7,458 | 14,909 |
|---|
| Site consolidation charges | 1,053 | 1,052 | 3,545 | 3,983 |
|---|
| Total non-GAAP adjustments to operating income | $18,729 | $14,055 | $50,947 | $49,645 |
|---|
| Operating income, excluding non-GAAP adjustments | $53,282 | $41,599 | $164,891 | $150,286 |
|---|
| Non-GAAP operating income as a % of revenue | 25.0% | 21.0% | 25.8% | 24.0% |
|---|
| Depreciation and amortization | $21,939 | $18,389 | $63,410 | $53,050 |
|---|
| Capital expenditures | $3,173 | $7,186 | $14,099 | $36,543 |
|---|
| Revenue | $600,685 | $615,060 | $1,811,323 | $1,847,931 |
|---|
| Operating income | 123,153 | 126,436 | 339,886 | 379,651 |
|---|
| Operating income as a % of revenue | 20.5% | 20.6% | 18.8% | 20.5% |
|---|
| Add back: | | | | |
|---|
| Amortization related to acquisitions | 19,198 | 19,818 | 55,581 | 58,712 |
|---|
| Acquisition, integration, and divestiture-related adjustments | 2,407 | 1,714 | 4,755 | 7,497 |
|---|
| Severance | (148) | 12,550 | 5,068 | 20,463 |
|---|
| Asset impairment | 693 | 552 | 22,390 | 1,064 |
|---|
| Site consolidation charges | 3,985 | 772 | 10,690 | 2,604 |
|---|
| Third-party legal and advisory costs and certain related items | 3,242 | 6,713 | 25,029 | 11,014 |
|---|
| Total non-GAAP adjustments to operating income | $29,377 | $42,119 | $123,513 | $101,354 |
|---|
| Operating income, excluding non-GAAP adjustments | $152,530 | $168,555 | $463,399 | $481,005 |
|---|
| Non-GAAP operating income as a % of revenue | 25.4% | 27.4% | 25.6% | 26.0% |
|---|
| Depreciation and amortization | $44,001 | $47,751 | $128,660 | $141,269 |
|---|
| Capital expenditures | $25,709 | $22,773 | $78,730 | $91,176 |
|---|
| Revenue | $190,693 | $196,879 | $570,014 | $574,389 |
|---|
| Operating income | 39,926 | 40,188 | 43,367 | 111,099 |
|---|
| Operating income as a % of revenue | 20.9% | 20.4% | 7.6% | 19.3% |
|---|
| Add back: | | | | |
|---|
| Amortization related to acquisitions | 8,265 | 10,802 | 100,675 | 32,363 |
|---|
| Acquisition, integration, and divestiture-related adjustments | - | 143 | - | 1,386 |
|---|
| Severance | 1,281 | 4,892 | 3,102 | 8,086 |
|---|
| Asset impairment | 91 | - | 6,449 | 25 |
|---|
| Site consolidation charges | 1,263 | 502 | 4,239 | 1,567 |
|---|
| Total non-GAAP adjustments to operating income | $10,900 | $16,339 | $114,465 | $43,427 |
|---|
| Operating income, excluding non-GAAP adjustments | $50,826 | $56,527 | $157,832 | $154,526 |
|---|
| Non-GAAP operating income as a % of revenue | 26.7% | 28.7% | 27.7% | 26.9% |
|---|
| Depreciation and amortization | $17,377 | $20,298 | $127,343 | $60,176 |
|---|
| Capital expenditures | $5,191 | $8,735 | $33,631 | $28,180 |
|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | |
| SCHEDULE 4 | |
| RECONCILIATION OF GAAP TO NON-GAAP | |
| SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED) | |
| (in thousands, except percentages) | |
| Research Models and Services | | | | |
| Discovery and Safety Assessment | | | | |
| Manufacturing Solutions | | | | |
| Unallocated Corporate Overhead | $(63,833) | $(76,763) | $(188,595) | $(196,357) |
| Add back: | | | | |
| Acquisition, integration, and divestiture-related adjustments | 772 | 4,082 | 3,663 | 7,719 |
| Severance | 3,527 | 6,443 | 5,103 | 9,237 |
| Asset impairment | - | - | 184 | - |
| Site consolidation charges | 767 | - | 1,436 | - |
| Third-party legal and advisory costs | (146) | - | 6,230 | - |
| Total non-GAAP adjustments to operating expense | $4,920 | $10,525 | $16,616 | $16,956 |
| Unallocated corporate overhead, excluding non-GAAP adjustments | $(58,913) | $(66,238) | $(171,979) | $(179,401) |
| Total | | | | |
| Revenue | $1,004,852 | $1,009,763 | $3,021,155 | $3,047,440 |
| Operating income | 133,799 | 117,405 | 308,602 | 395,034 |
| Operating income as a % of revenue | 13.3% | 11.6% | 10.2% | 13.0% |
| Add back: | | | | |
| Amortization related to acquisitions | 40,368 | 39,706 | 192,522 | 117,806 |
| Acquisition, integration, and divestiture-related adjustments | 3,179 | 5,939 | 8,432 | 16,939 |
| Severance | 4,796 | 26,536 | 16,937 | 41,471 |
| Asset impairment | 5,419 | 1,818 | 36,481 | 15,998 |
| Site consolidation charges | 7,068 | 2,326 | 19,910 | 8,154 |
| Third-party legal and advisory costs and certain related items | 3,096 | 6,713 | 31,259 | 11,014 |
| Total non-GAAP adjustments to operating income | $63,926 | $83,038 | $305,541 | $211,382 |
| Operating income, excluding non-GAAP adjustments | $197,725 | $200,443 | $614,143 | $606,416 |
| Non-GAAP operating income as a % of revenue | 19.7% | 19.9% | 20.3% | 19.9% |
| Depreciation and amortization | $85,164 | $88,198 | $325,035 | $259,637 |
| Capital expenditures | $35,580 | $38,721 | $130,202 | $157,351 |
| Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. | |
| Amortization related to acquisitions for the nine months ended September 27, 2025 includes $71.0 million of accelerated amortization of certain client relationships in the Biologics Solutions reporting unit within the Manufacturing Solutions segment. | |
| These adjustments are related to the evaluation and integration of acquisitions and divestitures, and primarily include transaction, advisory, certain third-party integration, certain compensation costs, and related costs; as well as fair value adjustments associated with contingent consideration arrangements. | |
| Third-party legal and advisory costs incurred within Unallocated Corporate are associated with the execution of the Cooperation Agreement with a shareholder. Within our DSA business, third-party legal costs incurred are associated with investigations by the U.S. government into the NHP supply chain. Additionally included within DSA, due to the utilization of NHPs, are reductions to the previous $27 million inventory charge incurred during fiscal 2024, to write down inventory associated with the Cambodia-sourced non-human primate matter from February 16, 2023, as a result of the cases being closed during fiscal 2025. | |
| Three Months Ended | Nine Months Ended |
|---|
| September 27, 2025 | September 28, 2024 | September 27, 2025 | September 28, 2024 |
|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | |
| SCHEDULE 5 | |
| RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED) | |
| (in thousands, except per share data) | |
| Net income available to Charles River Laboratories International, Inc. common shareholders | $54,422 | $68,679 | $132,217 | $225,996 |
| Add back: | | | | |
| Adjustment of redeemable noncontrolling interest | - | 379 | - | 1,081 |
| Incremental dividends attributable to noncontrolling interest holders | - | 599 | - | 9,621 |
| Non-GAAP adjustments to operating income | 62,632 | 82,315 | 302,104 | 209,332 |
| Venture capital and strategic equity investment (gains) losses and impairments, net | 20,201 | (2,507) | 31,594 | (9,171) |
| (Gain) loss on divestitures | - | - | (3,376) | 658 |
| Tax effect of non-GAAP adjustments: | | | | |
| Non-cash tax provision related to international financing structure | - | 292 | - | 1,504 |
| Enacted tax law changes | 3,236 | 3,596 | 3,236 | 3,596 |
| Tax effect of the remaining non-GAAP adjustments | (20,148) | (19,608) | (72,330) | (46,323) |
| Net income available to Charles River Laboratories International, Inc. common shareholders, excluding non-GAAP adjustments | $120,343 | $133,745 | $393,445 | $396,294 |
| Weighted average shares outstanding - Basic | 49,213 | 51,394 | 49,680 | 51,461 |
| Effect of dilutive securities: | | | | |
| Stock options, restricted stock units and performance share units | 213 | 189 | 186 | 252 |
| Weighted average shares outstanding - Diluted | 49,426 | 51,583 | 49,866 | 51,713 |
| Earnings per share attributable to common shareholders: | | | | |
| Basic | $1.11 | $1.34 | $2.66 | $4.39 |
| Diluted | $1.10 | $1.33 | $2.65 | $4.37 |
| Basic, excluding non-GAAP adjustments | $2.45 | $2.60 | $7.92 | $7.70 |
| Diluted, excluding non-GAAP adjustments | $2.43 | $2.59 | $7.89 | $7.66 |
| Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. | |
| This amount represents accretion adjustments of the Noveprim redeemable noncontrolling interest. | |
| This amount represents incremental declared dividends attributable to Noveprim noncontrolling interest holders who receive preferential dividends for fiscal year 2024. | |
| This amount excludes non-GAAP adjustments attributable to noncontrolling interest holders. | |
| The amount included in 2025 relates to a gain on the sale of a DSA site while the amount included in 2024 relates to a loss on the sale of a DSA site. | |
| This amount relates to the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure. | |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. |
|---|
| SCHEDULE 6 |
|---|
| RECONCILIATION OF GAAP REVENUE GROWTH |
|---|
| TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED) |
|---|
| Three Months Ended September 27, 2025 | Total CRL | RMS Segment | DSA Segment | MS Segment |
| Revenue growth, reported | (0.5)% | 7.9% | (2.3)% | (3.1)% |
| (Increase) decrease due to foreign exchange | (1.3)% | (1.4)% | (1.2)% | (2.0)% |
| Impact of divestitures | 0.2% | - % | 0.4% | - % |
| Non-GAAP revenue growth, organic | (1.6)% | 6.5% | (3.1)% | (5.1)% |
| Nine Months Ended September 27, 2025 | Total CRL | RMS Segment | DSA Segment | MS Segment |
| Revenue growth, reported | (0.9)% | 2.4% | (2.0)% | (0.8)% |
| (Increase) decrease due to foreign exchange | (0.5)% | (0.5)% | (0.5)% | (0.7)% |
| Impact of divestitures | 0.1% | - % | 0.2% | - % |
| Non-GAAP revenue growth, organic | (1.3)% | 1.9% | (2.3)% | (1.5)% |
| Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. |
| Impact of divestitures relates to the sale of a site within DSA. |
| Organic revenue growth is defined as reported revenue growth adjusted for divestitures and foreign exchange. |